Clearity Exhibits and Presents at The Society of Gynecologic Oncology Conference
During The Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women’s Cancer held in Austin, TX, The Clearity Foundation exhibited and presented at an educational seminar of over 250 conference attendees. Clearity founder, Dr. Laura Shawver presented an overview of Clearity’s profiling panel and interpretation capability utilizing the Diane Barton Database. The audience was particularly interested in several case studies that Dr. Shawver presented illustrating how Clearity’s process can assist patients and their physicians in making more informed choices for treatment of recurrence. Clearity’s exhibit booth afforded an additional opportunity to educate conference attendees about Clearity’s mission. The educational symposia in particular drove physicians and clinicians to the Clearity booth to learn more about profiling for recurrence.
The conference featured more than 400 scientific presentations in addition to lectures, workshops, symposia, surgical and education forums and interactive debates that focus on emerging science, clinical trials and treatment in the field of gynecologic oncology. Encouragingly from Clearity’s perspective, many of the scientific presentations included information about biomarkers and the need for targeted therapeutics and the right drug combinations to more effectively treat ovarian cancer. Presentations from the conference may be accessed online by clicking here. The slides from Clearity foundation’s presentation can be viewed here.
At the conference, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a “Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer.” When this study was reported at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2011, there was a significant improvement in progression free survival (PFS) after randomization in the olaparib group as compared to placebo, median 8.4 months versus 4.8 months, HR 0.35 (95% CI 0.25-0.49, p<0.00001). Dr. Ledermann reported an interim analysis that shows no difference in overall survival. The median overall survival in the olaparib group was 29.7 months as compared to 29.9 months in the placebo group. It should be noted that these data are not yet mature and Dr. Ledermann stated that at the time of analysis 21% of patients receiving olaparib remain on study as compared to only 3% of patients receiving placebo. These results were reported on-line in the New England Journal of Medicine at this link
To see our presentation slides please click here.
